Department of Cardiology, Thoraxcenter, Erasmus Medical Center, P.O. Box 2040, 3000, CA Rotterdam, The Netherlands.
Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
J Nucl Cardiol. 2020 Dec;27(6):2202-2209. doi: 10.1007/s12350-019-01598-y. Epub 2019 Feb 13.
Sympathetic overactivity has been linked to vasospastic angina (VSA), although the exact pathophysiology of VSA is poorly understood. The purpose of this study is to assess if renal sympathetic denervation (RDN) reduces cardiac sympathetic nerve activity with a subsequent beneficial effect on angina relief in patients with refractory VSA.
Cardiac sympathetic nerve activity was assessed prior to procedure and at 6 months post-procedure using iodine-123 labeled meta-iodobenzylguanidine (I-MIBG) imaging. The Seattle Angina questionnaire (SAQ) was used to assess the degree to which the disease impacts quality of life. No significant change was observed in early HMR (pre-RDN: 2.74 [2.10 to 3.21] vs 6 months post-RDN: 2.57 [2.20 to 3.00]; P = 0.76), and late HMR (pre-RDN: 2.56 [2.18 to 3.20] vs 6 months post-RDN: 2.36 [2.13 to 3.22]; P = 0.22). Additionally, no change was seen in WR (P = 0.22). SAQ results revealed significant improvements in perceived physical limitation, angina frequency, and quality of life at 6 months (P < 0.05 for all).
RDN resulted in improvements in angina class and quality of life at 6 months in patients with refractory VSA. RDN, however, did not result in significant changes in cardiac sympathetic nerve activity as measured using I-MIBG. The latter observation should be considered with caution given the small sample size of this study. Larger studies are needed to assess this further.
交感神经过度活跃与血管痉挛性心绞痛(VSA)有关,尽管 VSA 的确切病理生理学仍不清楚。本研究的目的是评估肾去交感神经(RDN)是否会降低心脏交感神经活性,并随后对难治性 VSA 患者的心绞痛缓解产生有益影响。
在进行程序之前和程序后 6 个月,使用碘-123 标记间碘苄胍(I-MIBG)成像评估心脏交感神经活性。西雅图心绞痛问卷(SAQ)用于评估疾病对生活质量的影响程度。在早期 HMR 中未观察到显著变化(RDN 前:2.74 [2.10 至 3.21] vs RDN 后 6 个月:2.57 [2.20 至 3.00];P = 0.76),晚期 HMR 也未观察到显著变化(RDN 前:2.56 [2.18 至 3.20] vs RDN 后 6 个月:2.36 [2.13 至 3.22];P = 0.22)。此外,WR 也没有变化(P = 0.22)。SAQ 结果显示,在 6 个月时,感知身体限制、心绞痛发作频率和生活质量均有显著改善(所有 P < 0.05)。
在难治性 VSA 患者中,RDN 在 6 个月时可改善心绞痛分级和生活质量。然而,RDN 并未导致 I-MIBG 测量的心脏交感神经活性发生显著变化。鉴于本研究的样本量较小,应谨慎考虑后者观察结果。需要更大的研究来进一步评估这一点。